News

If the FDA approves Sunovion’s APL-130277 come January, Parkinson’s patients will have a first oral treatment — and a first new treatment in more than a decade — for off episodes, those times of difficulties with movement despite taking treatments that stimulate dopamine receptors, like levodopa. “We think that…

People with inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, are at a higher-than-usual risk for Parkinson’s disease, a review study involving 8.9 million IBD patients suggests. The study, “The risk of Parkinson’s disease in inflammatory bowel disease: A…

In 2017, the United Kingdom’s National Institute for Health and Care Excellence (NICE) published its latest guidelines on how adult patients and their caregivers should manage Parkinson’s disease (PD). In a new commentary, four experts discuss the implications of some of these recommendations for both patients and healthcare professionals,…

The new law calling for the federal government to collect data on U.S. residents with neurological conditions such as Parkinson’s will help refine disease research and make care more accessible, the Michael J. Fox Foundation (MJFF) for Parkinson’s Research said. President Donal Trump recently signed into law the Labor,…

Sensile Medical, a subsidiary of Gerresheimer, is going to launch its wearable micro pump to deliver liquid medicines to patients in Europe who have advanced Parkinson’s disease. The medical device was given the European Union’s CE declaration of conformity, a prerequisite for a product to enter the European…

A new tool to measure fear of falling may help improve patients’ personalized care, reduce the risk of falls, and enhance physical and social activity among patients with Parkinson’s disease, a study reports. The study, “Differentiating cognitive or motor dimensions…

A newly identified small molecule compound, called SynuClean-D, can prevent the formation of toxic alpha-synuclein aggregates, disrupt the propagation of amyloid fibrils, and rescue nerve cells from alpha-synuclein-induced death in an animal model of Parkinson’s disease, a study shows. Given this particular activity, SynuClean-D may be a promising candidate…

Parkinson’s researchers need to focus on human cells and tissues, implement modern computer modeling approaches, and shift away from animal models, according to a recent study. Earlier transition from preclinical studies to clinical trials also could be beneficial, the study authors suggest. The study, “Parkinson’s disease…

With its recent award of £1 million (about $1.3 million USD), Parkinson’s UK continues to invest in Keapstone Therapeutics, bringing the biotechnology company closer to developing treatments for Parkinson’s and motor neuron disease (MND), it was announced. Keapstone officials also hope the funding, which will go toward…

Short-term supplementation of vitamin D in high doses may improve balance in people with Parkinson’s disease younger than 66, according to results of a Phase 2 pilot study. The study, “A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson’s…